Daiichi Sankyo and AstraZeneca’s (AZN) Enhertu has been recommended for approval in the European Union, or EU, as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca price target raised to 13,000 GBp from 12,000 GBp at Deutsche Bank
- Merck, AstraZeneca: FDA to extend PDUFA date for sNDA for LYNPARZA combo
- AstraZeneca’s anifrolumab receives FDA orphan designation
- AstraZeneca says Dato-DXd ‘continued to demonstrate encouraging responses’
- AstraZeneca’s Dato-DXd shows ‘durable efficacy’ in HER2-low patients
